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Abstract
Background: The adenoma-carcinoma sequence has its
molecular basis in several gene mutations of which K-ras
and p53 are of paramount importance. The aims of this
study were to evaluate whether these genetic alterations
can be detected in colonic lavage fluid from patients with
colorectal adenomas and carcinomas. Methods: In 45
patients with adenomas, 20 patients with colorectal car-
cinomas and 38 patients with non-neoplastic and nonin-
flammatory diseases of the colon p53 and K-ras muta-
tions were evaluated in colonic lavage fluid employing
single-strand confirmation polymorphism analysis and
dot-blot hybridization, respectively. Results: Mutations
of the K-ras and the p53 gene were found in 15.6% (p =
0.065) of patients with adenomas, in 25.0 % (p = 0.016) of
patients with carcinomas and in 2.6% in the control
group. Conclusion:  Genetic alterations in the colonic
lavage fluid could be an additional diagnostic tool for the
surveillance of patients with colorectal neoplasias.
Copyright © 2001 S. Karger AG, Basel
Introduction
Colorectal carcinoma is the second most frequent
cause of cancer-related deaths in men and women [1]. The
incidence rate in Germany is 62/100.000 inhabitants/
year. In early stages (Dukes A and B) definite cure is possi-
ble, whereas advanced stages (Dukes C and D) are associat-
ed with poor prognosis [1, 2]. The mortality rate has not
declined substantially during the last 50 years [3]. Present
diagnostic and therapeutic strategies aim at a substantial
reduction of the mortality by early detection of neoplastic
and preneoplastic lesions. Patients with resected adeno-
mas have an increased risk to develop metachronic adeno-
mas or carcinomas [4–6]. In asymptomatic patients, regu-
lar fecal occult blood testing (FOBT) decreases the mortali-
ty by 23% [7]. The positive predictive value of FOBT for
colorectal neoplasms (adenoma and carcinoma) ranges
between 22 and 58% [1]. The sensitivity of FOBT in
patients with colorectal adenomas is 20–40% [1], and
therefore unsatisfactory. Altogether, 40–50% of all colorec-
tal neoplasms are not detected by use of FOBT [8, 9]. Flexi-
ble sigmoidoscopy appears to be a more effective screening
procedure as it leads to a reduction of 60–80% of deaths
related to colorectal cancer [10–12]. However, the accep-
tance of flexible sigmoidoscopy in asymptomatic patients
is low [8, 9]. During endoscopy about 15% of colorectal
adenomas might be overlooked, in particular in patients
with multiple adenomas [13, 14]. These observations show
that current screening procedures are not sufficiently effec-
tive or practicable. Due to the drawbacks of the two main-
stays in the prevention of colorectal neoplasias, approaches
which employ molecular techniques might offer an im-
provement in the surveillance of patients with an increased
risk to develop colorectal carcinomas.
Colonic adenomas are the precusors of colonic carcino-
mas. The adenoma-carcinoma sequence has its molecular
basis in several mutations of tumor-suppressor genes and
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Table 1. Baseline characteristics of the study population
Female/
male
Age
mean B SD range
18/27 69B10 47–91
Colorectal carcinomas 7/13 65B12 86–49
Control 18/20 49B15 20–81
oncogenes, of which K-ras and p53 are among the most
important [15–18]. The present pilot study aimed to
assess the frequency of K-ras and p53 mutations in
colonic lavage fluid of patients with colonic adenomas
and compared it with the frequency of both mutations in
controls with non-neoplastic and noninflammatory co-
lonic disorders.
Patients and Methods
Study Population
The study population comprised 45 patients with colorectal ade-
nomas, 20 patients with colorectal carcinomas, 38 controls with non-
neoplastic and non-inflammatory diseases of the colon: irritable bow-
el syndrome (n = 15), hemorrhoids grade I or II (n = 13), diverticulo-
sis (n = 6), perianal lesions, e.g. anal fissures (n = 3) or submucosal
leiomyoma (n = 1). The baseline characteristics of the study popula-
tion are given in table 1. All patients gave informed consent to partic-
ipate in the study, which was approved by the local ethics commit-
tee.
In 22 patients one adenoma, in 8 patients two adenomas, in 6
patients three adenomas and in 5 patients four adenomas were
resected. One patient exhibited 5, one patient 6, two patients 8 and
one patient 10 adenomas, respectively. In 32 patients adenomas with
a diameter of 10 mm ore more were diagnosed. In patients with colo-
rectal carcinomas the distribution was as follows: rectum (n = 7), sig-
ma (n = 8), splenic flexur (n = 1), transverse colon (n = 1) and ascend-
ing colon (n = 3).
Patients with carcinomas were staged according to the Dukes
classification: Dukes A (n = 3), Dukes B (n = 5), Dukes C (n = 3) and
Dukes D (n = 9). Five patients had poorly and 15 patients well-diffen-
tiated adenocarcinomas. Two patients with colorectal carcinomas
had additional neoplasias: prostatic carcinoma (pT1c, pN0, pM0,
GI) diagnosed 2 years before and carcinoma of the appendix which
paralleled the carcinoma in the sigma (Dukes D).
Sampling and Processing of Colonic Lavage Fluid
During routine endoscopy the remaining solution which had been
administed orally prior to the endoscopic procedure was aspirated
and stored in a sterile vessel. The sample volume was between 50 and
500 ml. Immediately afterwards, the cellular components of the
colonic lavage fluid were cleaned by repeated centrifugation and gen-
tle aspiration in PBS solution. Genomic DNA was extracted using a
commercially available kit (QIAmp-DNA Mini, Qiagen, Hilden,
Germany).
Detection of K-ras and p53 Mutations
Both procedures have been described in detail elsewhere [19, 20].
Exon 5–8 of the p53-tumor-suppressor gene and codons 12 and 13 of
the first exon of the K-ras oncogene were amplified employing PCR.
p53 mutations were detected by use of single-strand confirmation
polymorphism analyses on 13.5% polyacrylamide gels with 10.0%
glyerol. K-ras point mutations were analysed employing dot-blot
hybridization of PCR products on positively charged nylon mem-
branes with different digoxigenin-labelled detection oligonucleo-
tides. The signal was detected by chemiluminescence on superim-
posed X-ray films with anti-digoxigenin-alkaline phosphatase Fab
fragments. DNA extracts from the cultured epithelial cell line Ha-
CaT, with known mutations in exon 5 and 8, codon 179 (C-T) and
codon 281 (CC-TT), and tissue specimens of carcinomas carrying the
different K-ras point mutations in codon 12 and 13 mutations served
as positive controls. Preparations of wild-type DNA from peripheral
leukocytes of healthy volunteers were used as negative controls.
Sequencing was performed on PCR products of DNA of the colonic
lavage fluid with a dideoxy-chain-breaking-methode (ABI 377 Se-
quencer) with specific sequencing PCRs.
Statistical Analysis
The statistical analysis were performed using the two-tailed Fish-
er’s exact test. Significance was accepted at a level of p ! 0.05.
Results
Mutations of the p53 gene were found in the colonic
lavage fluid of 3 patients with adenomas (6.6%) (p =
0.621), in 4 patients with colorectal carcinomas (20.0%)
(p = 0.044) and in one control (2.6%). K-ras mutations
were detected in 4 patients with adenomas (8.8%) (p =
0.121), in one patient with a carcinoma (5.0%) (p = 1.000)
but in none of the controls. If the results of both mutations
were pooled, 7 patients with adenomas (15.6%) (p =
0.065), 5 patients with carcinomas (25.0%) (p = 0.016)
and one patient in the control group (2.6%) displayed
genetic alterations in the colonic lavage fluid. p53 and K-
ras gene mutations were not detected simultaneously. The
frequencies of both gene mutations are listed in table 2.
The gene mutations in the colonic lavage fluid and the
tissue specimens were confirmed by the sequencing of the
PCR products.
The one patient in the control group who displayed the
p53 mutation (exon 5) in the lavage fluid was a 54-year-
old woman. She underwent diagnostic colonoscopy due to
a change in bowel habits. The macroscopic appeareance
of the colonic mucosa did not reveal any pathologic find-
ing. By extensive clinical evaluation (endoscopy of the
upper gastrointestinal tract, barium enema, abdominal
sonography, CT scan and X-ray of the thorax) a neoplasm
in any other part of the digestive tract, the liver and pan-
creas was ruled out. Furthermore, during a follow-up of
Colorectal adenomas
S.G.
K.J.
Gene Mutations in Colorectal Neoplasias Digestion 2001;63:229–233 231
Table 2. p53 and K-ras mutations in the study population
Samples p53 mutations
n %
K-ras mutations
n %
p53 and K-ras mutations
n %
45 3 6.6 4 8.8 7 15.6
Colorectal carcinomas 20 4 20.0 1 5.0 5 25.0
Control 38 1 2.6* 0 0.0 1 2.6
Percent values indicate the percentage of detected mutations within each group.
* For clinical details, see ‘Results’.
Table 3. Characteristics of patients with colorectal adenomas and K-ras or p53 mutations
Patient Age
years
Sex Adenomas Size of
adenomas
mm
Type of
adenomas
Histopathologic
classification
(dysplasia)
Mutations
p53 and K-ras
Other
neoplasms
70 M 10 5–15 tubulovillous severe K-ras: gly-cys 12 no
P.A. 78 F 8 2–15 tubulovillous mild K-ras: gly-asp 12 no
M.R. 59 M 1 40 tubulovillous severe K-ras: gly-val 12 no
S.E. 87 F 3 3 tubular mild K-ras: gly-asp 13 no
S.B. 72 M 1 5 tubular mild p53: exon 6 no
L.H. 79 M 1 8 tubulovillous mild p53: exon 6 yes*
V.R. 57 F 1 10 tubulovillous mild p53: exon 7 no
* Colonic adenocarcinoma resected 5 years prior to resection of adenomas.
Table 4. Characteristics of patients with colorectal carcinomas and K-ras or p53 mutations
Patient Age
years
Sex Localization of
the carcinoma
Type of
carcinoma
Differentiation
of the carcinoma
Dukes
classification 
Mutations:
p53 and K-ras
Other
neoplasms
82 M rectum adenocarcinoma moderate D K-ras: gly-asp 13 no
S.J. 59 M rectum adenocarcinoma moderate A p53: exon 7 no
B.J. 83 M rectum adenocarcinoma moderate B p53: exon 5 no
T.W. 75 M rectum adenocarcinoma poor C p53: exon 7 no
S.D. 54 M rectum adenocarcinoma moderate B p53: exon 7 no
more than 2 years no evidence for a neoplastic lesion was
found. The mother of the patient had died of pancreatic
carcinoma at the age of 67 years. Results of genetic analy-
sis of R122H, N29I, and A16V mutations in the cationic
trypsinogen gene (PRSS1) (EUROPAC, Liverpool) in the
patient’s serum, which could be present in patients with
hereditary pancreatitis, were negative. Detailed descrip-
tions of patients with colorectal adenomas and carcino-
mas who exhibited p53 or K-ras mutations are given in
tables 3 and 4, respectively.
Discussion
The histopathological alterations which can be ob-
served during the progression of colonic adenomas to car-
cinomas are mirrored by sequential molecular alterations
involving several genes, e.g. APC, K-ras, DCC and p53
[16–18]. In tissue specimens of sporadic colorectal carci-
nomas mutations of the tumor-suppressor gene p53 and
the oncogene K-ras are present in 70 and 50%, respective-
ly [16, 19, 20]. Both mutations play a key role in the ade-
noma-to-carcinoma sequence. Mutations result in ad-
232 Digestion 2001;63:229–233 Heinzlmann/Neynaber/Heldwein/
Folwaczny
vanced cellular proliferation and finally lead to aggressive
and invasive growth of colorectal carcinomas [21–23]. In
large and severely dysplastic adenomas K-ras mutations
were described more frequently than in smaller adenomas
[16]. This observation is compatible with a promoter
function of K-ras for the development of dysplastic
changes and the growth of small colonic adenomas. In
vitro, the inactivation of the Ras oncogene results in the
loss of the malignant phenotype in colonic carcinoma cell
lines [24]. The p53 mutation is possibly the last step in the
development of a colorectal carcinoma from an adenoma
[16]. Furthermore, the presence of this mutation is a nega-
tive prognostic marker for patients with colorectal carci-
nomas [23, 25, 26].
Sidransky and colleagues [27] found K-ras mutations
in 8 of 9 stool samples obtained from patients with colo-
rectal carcinomas and presence of K-ras mutations in the
tumor tissue. Similar results were reported in small series
by several other groups [28–34]. In summary, if the
respective mutations were present in the tumor tissue, the
latter could be detected in about 70% of the stool samples.
However, the extraction and amplification of tumor DNA
in stool samples is a problematical technical procedure,
which might produce false-negative results due to soilings
which can impair the amplification of genomic DNA. In
contrast, detection of genetic alterations in colonic lavage
fluid appears to be a more feasible and validated tech-
nique. This has been demonstrated in large patient
cohorts [28, 30, 35, 36]. Colonic lavage fluid probably
contains cellular elements from all parts of the gastro-
intestinal tract. It might therefore even be valuable for the
detection of gastric, pancreatic oder biliary carcinomas.
Furthermore, about 15% of all colorectal adenomas are
missed during endoscopy [13, 14]. Hence, this technique
might reduce the rate of false-negative results in the sur-
veillance of patients with colorectal neoplasias.
In the present study 15.6% (K-ras: 8.8%, p53: 6.6%) of
all patients with colorectal adenomas exhibited K-ras or
p53 mutations in the colonic lavage fluid, as compared to
2.6% in the control group (p = 0.065). Furthermore, there
was no correlation between the histopathologic degree of
dysplasia in the resected adenomas and the detection of
genetic alterations in the colonic lavage fluid: only two
patients with highly dysplastic adenomas displayed genet-
ic mutations in the colonic lavage fluid. Vice versa five
patients with severely dysplastic adenomas exhibited nei-
ther K-ras nor p53 mutations in the colonic lavage fluid
(p = 0.235). Presence of large adenomas (610 mm) [4–6]
or multiple adenomas [4, 6] are regarded as important risk
factors for the subsequent development of colorectal can-
cer. There was no correlation with these parameters: in 3
patients with presence of mutations multiple adenomas
were diagnosed and in 4 patients, displaying K-ras and/or
p53 mutations large adenomas were resected. In contrast,
in 23 patients who had large adenomas (p = 1.000) and in
25 patients with multiple adenomas genetic mutations
were not detected (p = 0.690).
In our group of patients with colorectal carcinomas
gene mutations were present in 25% (p53: 20.0%; K-ras:
5.0%). Therefore, the frequency of mutations in the
colonic lavage fluid in this study group was significantly
higher than in the controls (p = 0.016). In patients with
gene mutations in the colonic lavage fluid no correlation
with the histopathological differentiation of the carcino-
ma and the Dukes stage was found. One patient had a
poorly differentiated adenocarcinoma, whereas the re-
mainder of patients showed a higher degree of histologic
differentiation. Only two patients with carcinomas and
mutations in the colonic lavage fluid were in an advanced
Dukes stage: Dukes C and Dukes D, respectively. Inter-
estingly, all patients with colonic carcinomas exhibiting
genetic mutations had carcinomas of the rectum. This
correlation has not been demonstrated in previous re-
ports, and might be due to the fact that large amounts of
the lavage fluid are usually present in the rectum, as com-
pared to proximal parts of the colon. Thus, we cannot
exclude a sampling bias, e.g., epithelial cells from the rec-
tum might be overrepresented in the lavage fluid because
of the special anatomic situation with the rectal ampullae.
Moreover, this fluid is usually collected at the end of the
colonoscopy, which might result in faster processing of
DNA origination from the rectum as opposed to DNA
from upper parts of the colon.
In summary, due to the low prevalence of genetic alter-
ations in the colonic lavage fluid and the weak correlation
with macroscopic or histologic risk factors for the devel-
opment of colorectal carcinomas this approach does not,
at present, offer an advantage compared to standard sur-
veillance strategies of patients with colorectal adenomas.
Presence of mutations in the colonic lavage appears to be
highly specific for detection of neoplasias. Technical im-
provements and perhaps additional washings of particu-
lar areas might improve the sensitivity of our approach,
which is unsatisfactory low, thus for. Moreover, future
investigations will aim at the detection of mutations in
codon 61 of the K-ras gene and further genetic alterations
such as the inactivated and mutated APC tumor suppres-
sor gene. This approach could improve the identification
of patients with early gate-keeping events. However, long-
term follow-up of our patients, an expanded study popula-
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tion, the use of further genetic markers and the implemen-
tation of reliable DNA purification methods for other
body fluids, e.g. stool or plasma [37, 38], might enable
physicians to identify patients with a high risk for colorec-
tal cancer on a molecular basis.
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